GlassScriptPhysician profile
Howard I Baron
NPI 1497739601
$2,810.17
in general payments reported to CMS, 2019-2025
25 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $155 · 2021: $197 · 2022: $471 · 2023: $742 · 2024: $609 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $430.41 | 2022-2025 | Stelara, Tremfya |
| Genzyme Corporation | $332.36 | 2022-2025 | |
| Mirum Pharmaceuticals, INC. | $329.19 | 2022-2025 | Livmarli |
| Regeneron Healthcare Solutions, INC. | $306.89 | 2023 | Dupixent |
| Qol Medical, LLC | $233.72 | 2019-2024 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $213.91 | 2021-2025 | Gattex, Eohilia |
| Travere Therapeutics, INC. | $191.02 | 2019-2023 | Cholbam |
| Abbvie INC. | $141.71 | 2021-2023 | Skyrizi |
| Alexion Pharmaceuticals, INC. | $131.98 | 2019 | |
| Neuraxis, INC. | $76.05 | 2024 | |
| Nestle Healthcare Nutrition INC. | $69.79 | 2022 | |
| Albireo Pharma, INC. | $45.04 | 2023 | Bylvay |
| Alcresta Therapeutics, INC. | $42.04 | 2025 | Relizorb |
| Intra-Sana Laboratories | $37.41 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $34.52 | 2024 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $31.07 | 2025 | Smoflipid |
| Boston Scientific Corporation | $29.70 | 2020-2023 | |
| Ipsen Biopharmaceuticals, INC | $23.84 | 2023 | Bylvay |
| Sandoz INC. | $22.65 | 2023 | |
| Argon Medical Devices, INC. | $19.55 | 2022 | |
| Horizon Therapeutics Plc | $19.21 | 2023 | Actimmune |
| Applied Medical Technology INC | $17.61 | 2019 | |
| Evoendo, INC | $17.06 | 2023 | |
| Cook Medical LLC | $13.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Baron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.